Artiva Biotherapeutics Inc (ARTV)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$4.22+0.48%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · ARTV
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -56.7% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name operates in a high-miss-rate industry and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
ARTV — workforce reduction
Dated 2026-10-27
Costs Associated with Exit or Disposal Activities. On October 22, 2026, the board of directors of the Company approved the discontinuation of the Company’s development of AlloNK ® (AB-101), its non-genetically modified, allogeneic natural killer (NK) cell therapy candidate, as the Company conducts a process to explore strategic alternatives to maximize stockholder value, which includes a plan to implement a reduction of the Company’s workforce by approximately 94% of the Company’s current emp…
Why it matters: A completed cut may lower ongoing costs while Artiva reviews its options. The company has not reported the savings yet.
Supportive ifArtiva reports that it has completed the roughly 94% workforce cut. It also gives lower ongoing costs or a cash-use figure.
Worry ifArtiva reports that the workforce cut is delayed, smaller than planned, or has not lowered ongoing costs.
Why it matters: The $319.1 million cash figure is preliminary. The next report can confirm the amount and show costs after the program stop.
Worry ifThe 2026-Q3 report shows less than $319.1 million in cash, cash equivalents, and investments. Or, it reports exit costs that reduce cash further.
Less concerning ifThe report confirms at least $319.1 million in cash, cash equivalents, and investments. It reports no major exit costs.
Why it matters: Artiva stopped AlloNK development after longer-term responses fell short of its bar. The full report can show cash and costs after that decision.
Worry ifThe 2026-Q3 report shows cash below $319.1 million or rising costs tied to the program stop and workforce cut.
Less concerning ifThe 2026-Q3 report confirms cash near or above $319.1 million and lower costs after the program stop.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$204 on $10,000 · ±2.0% | How much price usually moves either way. |
| Bad day | $886 loss on $10,000 · 8.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,871 loss on $10,000 · 68.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.